Comparative Effects of Ibandronate and Paclitaxel on Immunocompetent Bone Metastasis Model

키워드

참고문헌 (48)

1. Mundy GR, "Mechanisms of bone metastasis", Cancer, 80(8Suppl), pp.1546~1556 (1997)
2. Bussard KM, "Ex-vivo analysis of the bone microenvironment in bone metastatic breast cancer", J Mammary Gland Biol Neoplasiam, 14, pp.387~395 (2009)
3. Kurth AA, "The effect of an osteolytic tumor on the threedimensional trabecular bone morphology in an animal model", Skeletal Radiol, 30, pp.94~98 (2001)
4. Alvarez E, "Properties of bisphosphonates in the 13762 rat mammary carcinoma model of tumor-induced bone resorption", Clin Cancer Res, 9, pp.5705~5713 (2003)
5. Bauss F, "Ibandronate in metastatic bone disease: a review of preclinical data", Anticancer Drugs, 16, pp.107~118 (2005)
6. Peltier S, "Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules", Pharm Res, 23, pp.1243~1250 (2006)
7. Shord SS, "Intravenous administration of paclitaxel in Sprague-Dawley rats: what is a safe dose?", Biopharm Drug Dispos, 27, pp.191~196 (2006)
8. Stearns ME, "Effects of alendronate and taxol on PC-3ML cell bone metastases in SCID mice", Invasion Metastasis, 16, pp.116~131 (1996)
9. Heldman AW, "Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis", Circulation, 103, pp.2289~2295 (2001)
10. Lalla S, "Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats", Osteoporos Int, 8, pp.97~103 (1998)
11. Russell RG, "Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy", Osteoporos Int, 19, pp.733~759 (2008)
12. Muthukumaran P, "Estradiol influences the mechanical properties of human fetal osteoblasts through cytoskeletal changes", Biochem Biophys Res Commun, 423, pp.503~508 (2012)
13. Coleman RE, "Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?", Eur J Cancer, 45, pp.1909~1915 (2009)
14. Diel IJ., "Antitumour effects of bisphosphonates: first evidence and possible mechanisms", Drugs, 59, pp.391~399 (2000)
15. Hall DG, "Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system", J Bone Miner Res, 9, pp.221~230 (1994)
16. Russell RG, "Ibandronate: pharmacology and preclinical studies", Bone, 38(4 Suppl 1), pp.S7~S12 (2006)
17. Kurth AA, "Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat", Bone, 30, pp.300~306 (2002)
18. Kurth AA, "Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis", J Bone Miner Metab, 25, pp.86~92 (2007)
19. Fan TM, "Intravenous aminobisphosphonates for managing complications of malignant osteolysis in companion animals", Top Companion Anim Med, 24, pp.151~156 (2009)
20. Yang X, "Ibandronate does not reduce the anabolic effects of PTH in ovariectomized rat tibiae: a microarchitectural and mechanical study", Bone, 48, pp.1154~1163 (2011)
21. Arrington SA, "Temporal changes in bone mass and mechanical properties in a murine model of tumor osteolysis", Bone, 38, pp.359~367 (2006)
22. Chanda D, "Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis", Mol Ther, 16, pp.871~878 (2008)
23. Mann KA, "Predicting distal femur bone strength in a murine model of tumor osteolysis", Clin Orthop Relat Res, 466, pp.1271~1278 (2008)
24. Neudert M, "Site-specific human breast cancer (MDA-MB-231) metastases in nude rats:model characterisation and in vivo effects of ibandronate on tumour growth", Int J Cancer, 107, pp.468~477 (2003)
25. Fleisch H, "The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat", Osteoporos Int, 6, pp.166~170 (1996)
26. Chen X, "Localized sclerotic bone response demonstrated reduced nanomechanical creep properties", J Mech Behav Biomed Mater, 17, pp.198~208 (2013)
27. Xiao Yang, "Morphological and Mechanical Changes in Ovariectomized Rat Tibia with Treatments of Ibandronate and Parathyroid Hormone", OSTEOPOROSIS, 8(3), pp.255~265 (2010), 대한골다공증학회
28. 이태용, "Effect of Ibandronate and hPTH on the Viscoelastic Response of Ovariectomized Rat Femur", OSTEOPOROSIS, 9(3), pp.222~230 (2011), 대한골다공증학회
29. Allen MJ, "Biochemical markers of bone metabolism in animals:uses and limitations", Vet Clin Pathol, 32, pp.101~113 (2003)
30. Jaganjac M, "The involvement of granulocytes in spontaneous regression of Walker 256 carcinoma", Cancer Lett, 260, pp.180~186 (2008)
31. Jung A, "Inhibition by diphosphonates of bone resorption induced by the Walker tumor of the rat", Cancer Res, 44, pp.3007~3011 (1984)
32. Lee T, "Predicting failure load of the femur with simulated osteolytic defects using noninvasive imaging technique in a simplified load case", Ann Biomed Eng, 35, pp.642~650 (2007)
33. Lee T, "Novel approach of predicting fracture load in the human proximal femur using non-invasive QCT imaging technique", Ann Biomed Eng, 37, pp.966~975 (2009)
34. Lee T, "Assessing the susceptibility to local buckling at the femoral neck cortex to age-related bone loss", Ann Biomed Eng, 37, pp.1910~1920 (2009)
35. Strube A, "Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption", Clin Cancer Res, 15, pp.3751~3759 (2009)
36. Halvorson KG, "Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer", J Pain Symptom Manage, 36, pp.289~303 (2008)
37. Steed H, "Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel", Pharmacogenomics, 8, pp.803~815 (2007)
38. Hall TJ, "Taxol inhibits osteoclastic bone resorption", Calcif Tissue Int, 57, pp.463~465 (1995)
39. Ermolaeva LA, "Toxic effect of an antitumor drug paclitaxel on morphofunctional characteristics of the liver in rats", Bull Exp Biol Med, 145, pp.263~265 (2008)
40. Tarumi W, "Ovarian toxicity of paclitaxel and effect on fertility in the rat", J Obstet Gynaecol Res, 35, pp.414~420 (2009)
41. Brennan TC, "Selective modification of bone quality by PTH, pamidronate, or raloxifene", J Bone Miner Res, 24, pp.800~808 (2009)
42. Chavassieux PM, "Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis", J Clin Invest, 100, pp.1475~1480 (1997)
43. Boissier S, "Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases", Cancer Res, 60, pp.2949~2954 (2000)
44. Fromigue O, "Bisphosphonates induce breast cancer cell death in vitro", J Bone Miner Res, 15, pp.2211~2221 (2000)
45. Ottewell PD, "Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone", Mol Cancer Ther, 8, pp.2821~2832 (2009)
46. Verdijk R, "Differential effects of bisphosphonates on breast cancer cell lines", Cancer Lett, 246, pp.308~312 (2007)
47. Winter MC, "Exploring the anti-tumour activity of bisphosphonates in early breast cancer", Cancer Treat Rev, 34, pp.453~475 (2008)
48. Zheng Y, "Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis", Bone, 40, pp.471~478 (2007)